Canada struggles to deliver cutting-edge therapies to patients

Canada’s healthcare system now faces a growing divide between scientific progress and patient access, highlighted by a recent approval for a gene therapy designed to halt vision loss in two children. Charmain Brown’s family discovered the therapy had received regulatory clearance, only to confront a system ill-prepared to provide it. The treatment’s existence, its proven potential, and official approval did not guarantee its availability, leaving years of uncertainty over eligibility, administration methods, and provincial coverage for costs.

This disconnect between medical innovation and real-world delivery is emerging as a core issue within Canada’s healthcare framework. Emerging treatments—including cell and gene therapies, regenerative medicine, and other advanced interventions—are moving from research settings into clinical practice, offering potential cures for conditions once considered only manageable. However, the evaluation process for these therapies remains rooted in outdated 20th-century models, proving inadequate for the demands of 21st-century medical solutions.

Regenerative treatments differ sharply from traditional pharmaceuticals. Many rely on living cells or custom-designed processes, making large-scale clinical trials for rare diseases impractical. Some therapies are even produced on a per-patient basis. The current fragmented system, where regulation, health technology assessment, pricing decisions, and adoption operate in isolation, introduces delays that can close critical treatment windows, particularly for newborns with rapidly progressing genetic disorders.

Case studies reveal systemic therapy access gaps

A detailed report from the Stem Cell Network examines three Canadian-developed therapies to illustrate the problem: a gene therapy for a fatal neonatal condition, a bioengineered skin replacement for severe burn injuries, and a personalized treatment for a rare pediatric neurodevelopmental disorder. Each case exposed structural weaknesses in the healthcare system, demonstrating the need for flexible approaches tailored to the specific therapy and patient needs.

The federal Pharmaceutical and Life Sciences Sector Task Force has already identified modernization as essential, recommending faster regulatory reviews, clearer innovation pathways, and support mechanisms for domestic advanced therapies. While the government is reviewing these suggestions, regenerative medicine must remain central to any response. Canada possesses world-class research institutions and clinical expertise, yet lacks a cohesive system to efficiently transition novel therapies from development to patient care.

True health sovereignty in Canada encompasses more than just manufacturing capabilities. It requires the ability to discover, assess, and deliver therapies to those who need them. Billions have been invested in biomanufacturing and life sciences, but the system remains disjointed. Regulation, assessment, pricing, and adoption continue as separate, uncoordinated steps, each managed by different agencies. The outcome is predictable: delays or outright barriers for patients in urgent need.

Collaboration needed to break treatment bottlenecks

These therapies cannot be treated as conventional drugs requiring minor adjustments. Hospitals must prepare specialized staff, facilities, and diagnostic tools. Regulatory bodies, health technology assessors, and insurers should collaborate wherever possible to eliminate bottlenecks. Funding models must account for the full lifecycle of treatment, including research, production, specialized care, ongoing monitoring, and patient travel expenses.

A practical first step involves expanding the Advanced Therapeutic Products framework to create coordinated pathways. These would span development, regulation, assessment, reimbursement, and long-term evidence collection, streamlining the entire process. Canada should also establish a dedicated route for homegrown innovations, ensuring early guidance, coordinated support, and prioritization without compromising safety standards. Failure to act risks driving talent and investment to nations with more adaptable systems.

Provincial governments have taken uneven steps toward integration. Ontario recently announced a dedicated fund for rare disease therapies, while Quebec has partnered with Biotech Medtech Canada to establish regional manufacturing hubs. However, inconsistencies in funding eligibility and reimbursement criteria across jurisdictions continue to frustrate patients and researchers alike. A 2023 survey by the Canadian Organization for Rare Disorders (CORD) found that 68% of respondents had faced delays in accessing approved therapies due to provincial policy gaps.